HomeAboutMediaCareersSite MapContactSearch
Geron
PatientsProductsTechnology & ScienceInvestors
print
  • Clinical Trial Information
    • Oncology
    • Telomerase Inhibitor Drug (GRN163L)
    • Telomerase Cancer Vaccine (GRNVAC1)
    • Regenerative Medicine
    • hESC - Derived Therapies
  • Disease Information
    • Cancer
    • Spinal Cord Injury
    • Heart Disease
    • Diabetes
  • Information Request

hESC - Derived Therapies

We have completed IND-enabling studies for hESC-derived oligodendrocytes for application in spinal cord injury. Upon FDA concurrence of the IND and Institutional Review Board approval at each clinical trial site, we expect to initiate a Phase I clinical trial.

Visionary Therapeutics
Home | About | Media | Careers | Site Map | Contact | Search
Patients | Products | Technology & Science | Investors
Legal Disclaimer
Copyright © Geron 2008. All rights reserved.
Site design and layout by BFW Interactive